GP KFPs / SAQs · mental-health
Anxiety disorders — KFP-style written assessment
KFP-style staged scenarios on anxiety disorders: screening and severity bands, excluding medical mimics, NICE stepped-care decisions, sertraline initiation with activation counselling, benzodiazepine limits in panic disorder, and measurement-based relapse prevention.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
Anxiety: screen with GAD-7, exclude the mimics, step care up — and keep measuring
KFP 1 (10 marks)
A 29-year-old teacher presents with six months of constant worry about work performance, difficulty controlling the worry, muscle tension and broken sleep. PHQ-9 is 6; GAD-7 is 8. She drinks five coffees daily. TFTs normal. [1] [16]
- Interpret her GAD-7 score — what does it support, what does it not exclude? (2) [2] [3]
- Which modifiable contributor deserves a trial before or alongside other treatment, and why? (2) [16]
- Outline NICE's step 1–2 plan for her. (5) [1]
Model answers
- A score of 8 falls below the cut-off of 10 that Cochrane pooling associates with sensitivity 0.64 / specificity 0.91 for GAD — so probability is lowered but not excluded; with six months of uncontrolled worry and somatic tension the clinical story supports GAD assessment regardless. The derivation study's sensitivity 89%/specificity 82% represents best-case; pooled real-world performance is more modest. [2] [3]
- Caffeine: systematic review shows a dose-dependent anxiogenic effect in healthy individuals, partly through caffeine-induced insomnia. Five cups daily is a plausible driver; a supervised reduction trial is free, safe and diagnostic. [16]
- Step 1: education about GAD and treatment options plus active monitoring — less severe presentations may improve with this alone. Step 2 if not improved: low-intensity interventions guided by preference — individual non-facilitated self-help (CBT-based materials), individual guided self-help (CBT materials supported by a trained practitioner over 5–7 sessions of 20–30 minutes), or CBT-principled psychoeducational groups. Review with repeat GAD-7 at each contact. [1]
References9ShowHide
- [2]Spitzer RL, Kroenke K, Williams JB et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine, 2006.PMID 16717171
- [3]Aktürk Z, Hapfelmeier A, Fomenko A et al. Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults. The Cochrane database of systematic reviews, 2025.PMID 40130828
- [5]Lewis G, Duffy L, Ades A et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA). The lancet. Psychiatry, 2019.PMID 31543474
- [6]Cardoner N, Gutiérrez-Rojas L, Saiz P et al. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness. Frontiers in pharmacology, 2025.PMID 39989902
- [10]Farris SG, Derby L, Kibbey MM Getting comfortable with physical discomfort: A scoping review of interoceptive exposure in physical and mental health conditions. Psychological bulletin, 2025.PMID 40014537
- [12]Lewis G, Marston L, Duffy L et al. Maintenance or Discontinuation of Antidepressants in Primary Care. The New England journal of medicine, 2021.PMID 34587384
- [16]Nascimento AOD, Silva CECD, Silva MLD et al. The Effects of Caffeine on Anxiety Behavior in Healthy Individuals: A Systematic Review of the Literature. Stress and health, 2026.PMID 41549915
- [18]García Álvarez Á, Riera Serra P, Ricci-Cabello I et al. Effectiveness and safety of focused deprescribing interventions targeting specific drug classes in older adults across clinical settings. Age and ageing, 2026.PMID 42607278
- [1]Bandelow B, Allgulander C, Baldwin DS et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2023.PMID 35900161